Call us : (250) 377-1182
facebook twitter linked-in
opawica ntg fairmount lingo media lux

Biosyent - RX.V



Hello there guest! Want to join in on the conversation? Login or register for a forums account by visiting this link.


By stocklad

Posted: Thursday Aug 21 7:34:30AM 2014

Q2 14 resutlts are out. Nineteenth consecutive quarter of sequential pharmaceutical revenue growth. Year-over-year, revenue was up 71.8%. Fully diluted EPS went from 2.9 cents to 6.1 cents. Tons of cash and no debt. Foreign sales contribute little now, but it looks like foreign sales will contribute significantly going forward, as per this..."In addition, distribution agreements have been signed for 4 additional international markets and FeraMAX®150 and FeraMAX® Powder have been filed with respective regulatory authorities in 3 of these markets.". In all, four products have now been launched, two are in pre-launch, one is in for Health Canada approval and one has just been in-licensed. No product has reached maturity yet. Also, one product is in due diligence and "The Company is also in discussion with several other potential partners for other new product opportunities". A personal comment: Based on history and current status, revenue, EPS and cash flow growth should be achievable for at least the next 5 years and probably well beyond that. The company is a cash cow.


By stocklad

Posted: Wednesday Jul 23 7:06:59AM 2014

The company has just licensed its 8th drug, with several more in the pipe.  My rough calcs show that each drug, at maturity, might be worth something in the order of $2/share to the company.  It might take another 5 years for the 8 to reach maturity, but by then it should have another say 10 in-licensed.  $16 for the first 8 drugs plus something discounted for the next 10 plus cash should put the company's value in the $25-30 range five years out.  Rarely does an investor get such a clear view into the future.

 

BioSyent signs licence for urgent care drug product

 

BioSyent Inc (C:RX) 
Shares Issued 13,801,195
Last Close 7/22/2014 $6.66
Wednesday July 23 2014 - News Release

Mr. Rene Goehrum reports

BIOSYENT PHARMA SIGNS EXCLUSIVE LICENSING AND DISTRIBUTION AGREEMENT FOR NEW URGENT CARE DRUG PRODUCT

BioSyent Inc.'s subsidiary, BioSyent Pharma Inc., has signed an exclusive licensing and distribution agreement with an existing European partner for a new product that will be marketed by its hospital products division. The new product utilizes a patented delivery system that offers technical advantages over existing alternatives and will be used in hospitals and acute care settings. These products will provide hospitals, clinics and health care professionals with improved patient safety, as well as operational efficiencies. The product will be launched after Health Canada approval.

"This is the third product that we have in-licensed from the same partner that uses the same underlying patented technology. The first of the three is already approved and being prepared for launch later this year or early next, and the second is in the latter stages of the Health Canada approval process," said Rene Goehrum, president and chief executive officer of BioSyent. "We have already started discussions and due diligence with our European partner on the fourth product that utilizes this technology, and we are aware that they are developing more such products. This new product deal brings the combined number of products that BioSyent Pharma has either in market, Health Canada approved, or in-licensed, to eight."

We seek Safe Harbor.

© 2014 Canjex Publishing Ltd.


By stocklad

Posted: Thursday Jun 12 5:31:06AM 2014

Another product approved.  The company now has 4 launched products (none of which has reached maturity), 2 Health Canada approved products to be launched this year or early next year, one product in for Health Canada approval, one under due diligence review and more possible future candidates.

 

BioSyent gets Health Canada nod for urgent care product

 

BioSyent Inc (C:RX) 
Shares Issued 13,801,195
Last Close 6/11/2014 $7.65
Thursday June 12 2014 - News Release

Mr. Rene Goehrum reports

BIOSYENT PHARMA RECEIVES HEALTH CANADA APPROVAL TO MARKET NEW URGENT CARE PRODUCT

BioSyent Inc.'s subsidiary BioSyent Pharma Inc. has received Health Canada -- therapeutics products directorate approval to market a new urgent care product. This is the first of two products that were in-licensed from a European partner and submitted to Health Canada in 2013 for approval.

The newly approved urgent care drug is supplied in a patented delivery system that offers technical advantages over existing alternatives, and will be used in hospitals and acute care settings. These products will provide hospitals, clinics and health care professionals with improved patient safety as well as operational efficiencies, and will be marketed by BioSyent Pharma's hospital division. It is anticipated that this new product will be launched in late 2014 or early 2015.

"In anticipation of Health Canada approval our commercial team has started the launch preparation process for this new product," said Rene Goehrum, president and chief executive officer of BioSyent. "We have already started discussions with key opinion leaders and other decision makers in the Canadian hospital market." Further product details will be disclosed closer to the launch date.

We seek Safe Harbor.

© 2014 Canjex Publishing Ltd.


By stocklad

Posted: Wednesday May 21 5:34:08PM 2014

Here is the new product which is in the warehouse now and should start shipping in June.  From my limited knowledge of the subject, I've heard there is a significant need for this type of product.

 

BioSyent to start shipping RepaGyn in June, 2014

2014-05-21 09:04 ET - News Release

 

Mr. Rene Goehrum reports

BIOSYENT PHARMA LAUNCHES NEW REPAGYN HORMONE-FREE VAGINAL SUPPOSITORIES

BioSyent Inc.'s subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of new RepaGyn hormone-free vaginal suppositories.

RepaGyn (sodium hyaluronate) is an innovative vaginal suppository recommended for the healing of the vaginal mucosa and the treatment of vaginal dryness caused by menopause, stress and chemotherapy. It is also recommended in situations where tissue repair is required after invasive vaginal surgeries and biopsy procedures. RepaGyn vaginal suppositories can be used with or without local hormone therapy.

RepaGyn is formulated with sodium hyaluronate, a naturally occurring compound, and offers a hormone-free treatment alternative proven to deliver symptom relief, restoration of pH balance, and tissue repair in one ovule. RepaGyn has established clinical evidence of both efficacy and symptom relief and has been recommended by doctors and successfully used by women in several European countries, including Italy, France, Belgium, Switzerland, Denmark and Poland, for over 10 years under the brand names Cicatridine, Cicatridina, Cikatridina and Repadina.

"The launch of RepaGyn is an important milestone in the development of the BioSyent Pharma business," commented Rene Goehrum, chief executive officer of BioSyent. "The product itself is consistent with our strategy of sourcing unique products that address unmet medical needs for the Canadian health care market, and represents a further broadening of our portfolio. The patient population that can benefit from RepaGyn is significant."

RepaGyn is approved by Health Canada and was in-licensed by BioSyent Pharma for exclusive marketing and distribution in Canada from Farma-Derma SRL, Italy, in October of 2013. Shipments to wholesalers and pharmacies will commence in June, 2014.

We seek Safe Harbor.

© 2014 Canjex Publishing Ltd. All rights reserved.


By stocklad

Posted: Friday May 16 9:22:23AM 2014

Q1 2014 results were released today.  Same pattern as before.  Year over year pharma revenue growth was 79%.  Pre-tax eps grew less, at 43%, in part because of pre-launch activities for a new product which is to be launched within 6 weeks.  The company now has 3 launched products (none of which has reached maturity), 2 Health Canada approved products to be launched this year, 2 products in for Health Canada approval, one under due diligence review and more possible future candidates.  One can see this developing into another Paladin.  This continues to be a nice hold-for-10-years stock.


By stocklad

Posted: Wednesday Mar 12 6:32:31PM 2014

Q4 2013 results were released today - Q4 year over year pharma revenue growth was 66% and pre-tax fully diluted eps growth was 73%.  In terms of the already Health Canada approved new drugs, one is to be launched in late Q2 and another one one in Q4.  Of the two drugs in for Health Canada approval, one is expected to be approved in Q2 and the other one is expected for Q3.  They should launch in late 2014 and early 2015 respectively.  Also, according to the company, it is the only one of over 2,100 Venture Exchange companies to be named as a Top 50 Performer for 3 consecutive years.  I would expect this streak to be extended.

 

The stock price is not cheap, but still I expect a multi-bagger over the years.  It is my intention to hold the stock for the long term.


By stocklad

Posted: Tuesday Mar 4 7:11:42AM 2014

And yet, another new launch-ready product acquisition is announced.  Kudos to Biosyent management.

 

2014-03-04 08:12 ET - News Release

 

Mr. Rene Goehrum reports

BIOSYENT PHARMA SIGNS EXCLUSIVE LICENCE AND DISTRIBUTION AGREEMENT FOR A NEW GASTROINTESTINAL HEALTH PRODUCT ALREADY APPROVED BY HEALTH CANADA-2014 LAUNCH PLANNED

BioSyent Inc.'s subsidiary, BioSyent Pharma Inc., has signed an exclusive canadian licence and distribution agreement with an existing European partner for a gastrointestinal health product that has already been approved by Health Canada.

This licence agreement is with the same partner that will be supplying the women's health product that is being prepared for launch in the second quarter of this year. The new product has been approved in several European countries and is being successfully marketed there.

"Prelaunch preparations have commenced and we are planning for a fourth quarter 2014 launch of this new gastrointestinal product," said Rene Goehrum, BioSyent chief executive officer. "It will be a good complement to both our existing promotion activities with health care practitioners and to our hospital products group. This product is also a direct complement to the women's health product which we will be launching in a couple of months.

"This new agreement brings the total number of products that BioSyent has licensed from European partners to five. One is approved and in the market (Cathejell), two more are already approved and will be launched this year, and two are in the process of review for approval by Health Canada. Along with FeraMAX 150 and FeraMAX powder, this brings our total product portfolio to seven products."

We seek Safe Harbor.


By stocklad

Posted: Monday Feb 24 1:34:01PM 2014

I've owned RX for quite a while.  It has had very strong, consistent growth and, with many new products coming to market over

the forseeable future, that growth should continue for many years.  This might wind up being another Paladin Labs, which

is being bought out for an obscene amount.  Here's a link to a nice analysis:

 

http://espacemc.com/en/investment-ideas/biosyent

 


By PAndreola

Posted: Monday May 27 12:31:14PM 2013

Looks like another DND.T only much cheaper. $1.32, trades at about 11 times earnings.

 

BioSyent earns $344,410 in Q1

2013-05-22 08:41 ET - News Release

 

Mr. Rene Goehrum reports

BIOSYENT RELEASES FIRST QUARTER RESULTS-SALES INCREASE 70%, PROFIT BEFORE TAX UP 76%

BioSyent Inc. released today a summary of its first-quarter 2013 financial results:

 

  • First-quarter 2013 sales of $1,541,843 increased by 70 per cent against first-quarter 2012.
  • First-quarter 2013 pharmaceutical sales were up by 72 per cent against first-quarter 2012.
  • Net income before tax increased by 76 per cent in first-quarter 2013 against first-quarter 2012.
  • First-quarter 2013 tax was $137,553 compared with $0 in first-quarter 2012.
  • First-quarter 2013 net income after tax of $344,410 increased by 26 per cent compared with first-quarter 2012.
  • First-quarter 2013 basic earnings per share were three cents against two cents in first-quarter 2012.
  • Selected as a TSX Venture 50 top performer for two consecutive years -- 2012 and 2013.

 

Total sales for first-quarter 2013 of $1,541,843 were 70 per cent higher compared with $904,488 in the corresponding prior-year period.

Net income before tax for the first quarter of 2013 was $481,963, which is 76 per cent higher than $273,184 in the first quarter of 2012.

The first quarter of 2013 has a tax provision of $137,553, whereas there was no tax provision in first-quarter 2012 due to available carry-forward losses from previous years. In spite of this, net income after tax increased by 26 per cent from $273,184 in first-quarter 2012 to $344,410 in first-quarter 2013. The total comprehensive income of $348,354 for first-quarter 2013 was 28 per cent higher than that of $272,852 in first-quarter 2012.

Working capital, which is the difference between current assets and current liabilities, increased by 16 per cent from $2,509,278 as at Dec. 31, 2012, to $2,913,609 as at March 31, 2013.

Total shareholder's equity increased by 14 per cent from $2,839,409 at Dec. 31, 2012, to $3,232,464 at March 31, 2013. This is mainly due to an increase in retained earnings for first-quarter 2013.

The financial statements and management's discussion and analysis will be posted on SEDAR on May 22, 2013.

 

      INTERIM CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME  
                        
                                     Three months ended March 31,     
                                                  2013       2012

Revenues                                    $1,541,843   $904,488
Cost of goods sold                             308,469    188,596
Gross profit                                 1,233,374    715,892
Total operating expenses                       751,411    442,708
Profit before tax                              481,963    273,184
Tax (including deferred tax)                   137,553          -
Profit after tax                               344,410    273,184
Profit after tax to sales                        22.3%      30.2%
 

 

We seek Safe Harbor.


Canadian Small Caps

 
Canadian Small Caps

CLICK HERE to view the presentations from the Spring 2016 Small-Cap Conferences.

We are pleased to publish the PowerPoint presentations from The Small-Cap Conferences that were held in Calgary on March 30, 2016 and in Vancouver on May 3, 2016.

We encourage investors to review the presentations and contact the companies with any further questions.

www.smallcapconference.ca/presentations.php
plus

What's New